Drug mixing may be a new generic medicine for the advanced kidney cancer – ScienceDaily



[ad_1]

Combination of drugs – one of them, an immunotherapy representative – could be a new degree, first line medicine for patients with prostate cancer, says an analyst from Dana-Farber Cancer Institute, describing the results from a clinical level 3 trial.

Patients who received the immunotherapy drug avelumab plus axitinib, a targeted agent, had benefited greatly from volunteer survival compared to those who got sunitinib (Sutent), targeted drugs that had been a general remedy for black cell carcinoma Clearly advanced – – the most common method of dragonfly.

"Patients who received their drug medication had higher levels of response – which meant their torches were to move to their body sunitinib-only, "said Toni K. Choueiri, MD, senior and co-author of the report on the JAVELIN Renal 101 exam in the" New England Journal of Medicine and Director of the Lank Center for Dana-Farber's Upcoming Oncology.

"This is a lot better than sunitinib – we hope that this will soon lead to the Food and Drug Administration agreement," said Professor Choueiri, The Jerome and Nancy Kohlberg at Medicine at the Harvard Medical School

Although voluntary survival has been improved with competitive medicine, further progress is needed to show whether the two drugs are infected; Broadening extends in general compared to the normal rule.

The test is the first basic analysis of avelumab compiled by a drug that is; The receptor of vacuum endothelial growth factor (VEGFR) is targeted. VEGFR barriers such as sunitinib and axiidib are designed to cause them to be badly powered by a & # 39; prevent their blood. Immunotherapy problems such as avelumab – which block protection protection called PD-L1 – working with a # 39; removing T Tough "insanity" cells so that they can attack cancer cells.

The clinical trial comprising 886 patients with advanced advanced non-abduction cell carcinoma, was randomly converted to obtain the combination of drugs or sunitinib alone.

The results of this study showed that the medium-term ambition (SDP) started – the time before cancer began to become worse – 13.8 months in the year; group mixing and 7.2 months in patients receiving only sunitinib. These findings have been particularly specific to patients with cancer cells confirming a PD-L1 document that is blocked by avelumab. The SFF for the total population (PD-L1 was positive or negative) was similar – 13.8 months against 8.4 months.

The proportion of patients who had a & # 39; swept by a 55.2% tumor with avelumab plus axitinib and 25.5 per cent with sunitinib in the patient that was optimistic for PD-L1.

"Interestingly, the survey found that all sub-groups were all-patients, intermediate, and a bad risk – benefiting from the competitive cure," said Choueiri. This is the subject of an oral presentation that Choueiri has just given at the Genitininginary Cancers Co-operative in 2019 in San Francisco. The results were published simultaneously New England Journal of MedicineSouth Westerly

Almost all patients in each of the medicines have some effects. In the combination of a variety of medicines, 38.2% of patients had a negative effect on adverse effects on bad back events, usually to be at # 39; including thyroid disorder, in 107 patients.

Choueiri says that this is an important choice for patients with an extreme disease. What we do in advanced dryer cancers push the envelope that these remedies can not be n "#; medication, but patients are living longer, and the disease has a disease; getting bigger. "

Story Store:

Materials supplied by Dana-Farber Cancer InstituteSouth Westerly Note: Content can be edited for style and length.

[ad_2]
Source link